Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy)

An experimental study

Salil K. Bhattacharya, Arunabh Bhattacharya, Shibnath Ghosal

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Methylenedioxymethamphetamine (MDMA), commonly known as Ecstasy, is widely abused as a recreational agent. Reports of death following MDMA intake has aroused serious concern. Although some of the clinical symptoms of MDMA toxicity include severe anxiety, panic, excitation and agitation, behavioural studies on the drug are sparse and incomplete. The present study investigated the anxiogenic activity of MDMA in rats, using yohimbine (2 mg/kg, i.p.) as the standard anxiogenic agent for comparison. The experimental methods used were the open-field, elevated plus-maze, social interaction and novelty-suppressed feeding latency tests, all the tests being experimentally validated as rodent models of clinical anxiety. In addition, the effect of MDMA was assessed on rat brain tribulin activity in terms of endogenous monoamine oxidase (MAO) A and B inhibition. Tribulin has been postulated to function as an endogenous marker of anxiety. MDMA (5 and 10 mg/kg i.p.) reduced ambulation and rears, and increased immobility and defaecation, in the open-field test. These doses of MDMA produced a dose-related decrease in the number of entries and time spent on the open arms of the elevated plus maze, reduced social interaction in paired rats and increased the feeding latency time in an unfamiliar environment in food deprived rats. A qualitatively similar response was induced by yohimbine in all these test parameters. Both MDMA (5 and 10 mg/kg, i.p.) and yohimbine (2 mg/kg, i.p.) increased rat brain tribulin activity, the increase in the MAO A inhibitor component being more than that on the MAO B inhibitor component. Several anxiogenic agents induce a similar response, as does anxiety associated with addictive drug withdrawal. The anxiogenic effects of MDMA and yohimbine on the elevated plus maze were inhibited by the benzodiazepine anxiolytic lorazepam (0.25 mg/kg, i.p.). However, the 5-HT(1A) receptor agonist-antagonist, buspirone (2.5 mg/kg, i.p.), selectively inhibited the anxiogenic effect of MDMA. Earlier studies have indicated that MDMA has significant effect on rat brain 5-HT(1A) receptors and induces an increase in serotonergic activity in this species. The results of the present study indicate that MDMA induces significant anxiogenic response in rats which may involve the serotonergic neurotransmitter system.

Original languageEnglish (US)
Pages (from-to)217-237
Number of pages21
JournalBiogenic Amines
Volume14
Issue number3
StatePublished - 1998
Externally publishedYes

Fingerprint

N-Methyl-3,4-methylenedioxyamphetamine
Yohimbine
Monoamine Oxidase
Anxiety
Receptor, Serotonin, 5-HT1A
Monoamine Oxidase Inhibitors
Interpersonal Relations
Brain
Buspirone
Lorazepam
Panic
Defecation
Anti-Anxiety Agents
Benzodiazepines
Pharmaceutical Preparations
Walking
Neurotransmitter Agents
Rodentia

Keywords

  • Anxiety
  • Buspirone
  • Ecstasy
  • Lorazepam
  • Methylenedioxymethamphetamine
  • Tribulin
  • Yohimbine

ASJC Scopus subject areas

  • Neuroscience(all)
  • Pharmacology

Cite this

Bhattacharya, S. K., Bhattacharya, A., & Ghosal, S. (1998). Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy): An experimental study. Biogenic Amines, 14(3), 217-237.

Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy) : An experimental study. / Bhattacharya, Salil K.; Bhattacharya, Arunabh; Ghosal, Shibnath.

In: Biogenic Amines, Vol. 14, No. 3, 1998, p. 217-237.

Research output: Contribution to journalArticle

Bhattacharya, SK, Bhattacharya, A & Ghosal, S 1998, 'Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy): An experimental study', Biogenic Amines, vol. 14, no. 3, pp. 217-237.
Bhattacharya, Salil K. ; Bhattacharya, Arunabh ; Ghosal, Shibnath. / Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy) : An experimental study. In: Biogenic Amines. 1998 ; Vol. 14, No. 3. pp. 217-237.
@article{189d485d41bc4244a23162892c3fa7fe,
title = "Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy): An experimental study",
abstract = "Methylenedioxymethamphetamine (MDMA), commonly known as Ecstasy, is widely abused as a recreational agent. Reports of death following MDMA intake has aroused serious concern. Although some of the clinical symptoms of MDMA toxicity include severe anxiety, panic, excitation and agitation, behavioural studies on the drug are sparse and incomplete. The present study investigated the anxiogenic activity of MDMA in rats, using yohimbine (2 mg/kg, i.p.) as the standard anxiogenic agent for comparison. The experimental methods used were the open-field, elevated plus-maze, social interaction and novelty-suppressed feeding latency tests, all the tests being experimentally validated as rodent models of clinical anxiety. In addition, the effect of MDMA was assessed on rat brain tribulin activity in terms of endogenous monoamine oxidase (MAO) A and B inhibition. Tribulin has been postulated to function as an endogenous marker of anxiety. MDMA (5 and 10 mg/kg i.p.) reduced ambulation and rears, and increased immobility and defaecation, in the open-field test. These doses of MDMA produced a dose-related decrease in the number of entries and time spent on the open arms of the elevated plus maze, reduced social interaction in paired rats and increased the feeding latency time in an unfamiliar environment in food deprived rats. A qualitatively similar response was induced by yohimbine in all these test parameters. Both MDMA (5 and 10 mg/kg, i.p.) and yohimbine (2 mg/kg, i.p.) increased rat brain tribulin activity, the increase in the MAO A inhibitor component being more than that on the MAO B inhibitor component. Several anxiogenic agents induce a similar response, as does anxiety associated with addictive drug withdrawal. The anxiogenic effects of MDMA and yohimbine on the elevated plus maze were inhibited by the benzodiazepine anxiolytic lorazepam (0.25 mg/kg, i.p.). However, the 5-HT(1A) receptor agonist-antagonist, buspirone (2.5 mg/kg, i.p.), selectively inhibited the anxiogenic effect of MDMA. Earlier studies have indicated that MDMA has significant effect on rat brain 5-HT(1A) receptors and induces an increase in serotonergic activity in this species. The results of the present study indicate that MDMA induces significant anxiogenic response in rats which may involve the serotonergic neurotransmitter system.",
keywords = "Anxiety, Buspirone, Ecstasy, Lorazepam, Methylenedioxymethamphetamine, Tribulin, Yohimbine",
author = "Bhattacharya, {Salil K.} and Arunabh Bhattacharya and Shibnath Ghosal",
year = "1998",
language = "English (US)",
volume = "14",
pages = "217--237",
journal = "Biogenic Amines",
issn = "0168-8561",
publisher = "Society of Integrated Sciences",
number = "3",

}

TY - JOUR

T1 - Anxiogenic activity of methylenedioxymethamphetamine (Ecstasy)

T2 - An experimental study

AU - Bhattacharya, Salil K.

AU - Bhattacharya, Arunabh

AU - Ghosal, Shibnath

PY - 1998

Y1 - 1998

N2 - Methylenedioxymethamphetamine (MDMA), commonly known as Ecstasy, is widely abused as a recreational agent. Reports of death following MDMA intake has aroused serious concern. Although some of the clinical symptoms of MDMA toxicity include severe anxiety, panic, excitation and agitation, behavioural studies on the drug are sparse and incomplete. The present study investigated the anxiogenic activity of MDMA in rats, using yohimbine (2 mg/kg, i.p.) as the standard anxiogenic agent for comparison. The experimental methods used were the open-field, elevated plus-maze, social interaction and novelty-suppressed feeding latency tests, all the tests being experimentally validated as rodent models of clinical anxiety. In addition, the effect of MDMA was assessed on rat brain tribulin activity in terms of endogenous monoamine oxidase (MAO) A and B inhibition. Tribulin has been postulated to function as an endogenous marker of anxiety. MDMA (5 and 10 mg/kg i.p.) reduced ambulation and rears, and increased immobility and defaecation, in the open-field test. These doses of MDMA produced a dose-related decrease in the number of entries and time spent on the open arms of the elevated plus maze, reduced social interaction in paired rats and increased the feeding latency time in an unfamiliar environment in food deprived rats. A qualitatively similar response was induced by yohimbine in all these test parameters. Both MDMA (5 and 10 mg/kg, i.p.) and yohimbine (2 mg/kg, i.p.) increased rat brain tribulin activity, the increase in the MAO A inhibitor component being more than that on the MAO B inhibitor component. Several anxiogenic agents induce a similar response, as does anxiety associated with addictive drug withdrawal. The anxiogenic effects of MDMA and yohimbine on the elevated plus maze were inhibited by the benzodiazepine anxiolytic lorazepam (0.25 mg/kg, i.p.). However, the 5-HT(1A) receptor agonist-antagonist, buspirone (2.5 mg/kg, i.p.), selectively inhibited the anxiogenic effect of MDMA. Earlier studies have indicated that MDMA has significant effect on rat brain 5-HT(1A) receptors and induces an increase in serotonergic activity in this species. The results of the present study indicate that MDMA induces significant anxiogenic response in rats which may involve the serotonergic neurotransmitter system.

AB - Methylenedioxymethamphetamine (MDMA), commonly known as Ecstasy, is widely abused as a recreational agent. Reports of death following MDMA intake has aroused serious concern. Although some of the clinical symptoms of MDMA toxicity include severe anxiety, panic, excitation and agitation, behavioural studies on the drug are sparse and incomplete. The present study investigated the anxiogenic activity of MDMA in rats, using yohimbine (2 mg/kg, i.p.) as the standard anxiogenic agent for comparison. The experimental methods used were the open-field, elevated plus-maze, social interaction and novelty-suppressed feeding latency tests, all the tests being experimentally validated as rodent models of clinical anxiety. In addition, the effect of MDMA was assessed on rat brain tribulin activity in terms of endogenous monoamine oxidase (MAO) A and B inhibition. Tribulin has been postulated to function as an endogenous marker of anxiety. MDMA (5 and 10 mg/kg i.p.) reduced ambulation and rears, and increased immobility and defaecation, in the open-field test. These doses of MDMA produced a dose-related decrease in the number of entries and time spent on the open arms of the elevated plus maze, reduced social interaction in paired rats and increased the feeding latency time in an unfamiliar environment in food deprived rats. A qualitatively similar response was induced by yohimbine in all these test parameters. Both MDMA (5 and 10 mg/kg, i.p.) and yohimbine (2 mg/kg, i.p.) increased rat brain tribulin activity, the increase in the MAO A inhibitor component being more than that on the MAO B inhibitor component. Several anxiogenic agents induce a similar response, as does anxiety associated with addictive drug withdrawal. The anxiogenic effects of MDMA and yohimbine on the elevated plus maze were inhibited by the benzodiazepine anxiolytic lorazepam (0.25 mg/kg, i.p.). However, the 5-HT(1A) receptor agonist-antagonist, buspirone (2.5 mg/kg, i.p.), selectively inhibited the anxiogenic effect of MDMA. Earlier studies have indicated that MDMA has significant effect on rat brain 5-HT(1A) receptors and induces an increase in serotonergic activity in this species. The results of the present study indicate that MDMA induces significant anxiogenic response in rats which may involve the serotonergic neurotransmitter system.

KW - Anxiety

KW - Buspirone

KW - Ecstasy

KW - Lorazepam

KW - Methylenedioxymethamphetamine

KW - Tribulin

KW - Yohimbine

UR - http://www.scopus.com/inward/record.url?scp=0031842014&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031842014&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 217

EP - 237

JO - Biogenic Amines

JF - Biogenic Amines

SN - 0168-8561

IS - 3

ER -